A dose-response clinical trial is a type of clinical trial that investigates the relationship between the dosage of a therapeutic and its effectiveness in patients. North America leads dose-response studies with 43.8% of trials. This region is followed by Asia-Pacific (31.6%), Europe (27.1%), the Middle East and Africa (13.8%) and South and Central America with 0.03%. The top country for dose-response studies was the US, with 41.4% of trials.
When exploring the field of drug development, the US dominates dose-response studies, as US sites and institutions conduct a significant amount of research and have the infrastructure and resources to carry out dose-response studies.
The US has a robust regulatory framework that encourages and supports clinical research, including dose-response studies. Additionally, the US also has a diverse population, which allows for a more comprehensive understanding of how different individuals respond to different doses of medications.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
For dose-response trials, Phase I trials outnumbered all other phases with 45.6% of trials. This was followed by Phase II (36.5%), Phase III (10.1%) and then Phase IV with 0.1% of trials. Earlier phases are expected to have higher trial counts in comparison to later phases. Early-phase trials, especially Phase I, focus on evaluating the safety profile of a drug candidate in humans.
Additionally, dose-response trials in the early phases help to find the right dose for patients. Early-phase trials are typically conducted with a relatively small number of
subjects, making them more manageable and cost-effective than the larger trials in later phases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
